奥希替尼与卡博替尼联合治疗一名对克唑替尼耐药后出现多个MET二次位点突变的EGFR突变型肺腺癌患者 - Suppr

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

作者信息

Kang Jin, Chen Hua-Jun, Wang Zheng, Liu Jing, Li Bing, Zhang Tengfei, Yang Zhenfan, Wu Yi-Long, Yang Jin-Ji

机构信息

Guangdong Cardiovascular Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.

出版信息

J Thorac Oncol. 2018 Apr;13(4):e49-e53. doi: 10.1016/j.jtho.2017.10.028. Epub 2017 Nov 8.

DOI:10.1016/j.jtho.2017.10.028

PMID:29128427

Abstract

摘要

相似文献

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

J Thorac Oncol. 2018 Apr;13(4):e49-e53. doi: 10.1016/j.jtho.2017.10.028. Epub 2017 Nov 8.

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.

J Thorac Oncol. 2017 Jul;12(7):e85-e88. doi: 10.1016/j.jtho.2017.02.020. Epub 2017 Mar 6.

Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.

Lung Cancer. 2018 Apr;118:105-110. doi: 10.1016/j.lungcan.2018.02.007. Epub 2018 Feb 13.

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.

J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y.

Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.

Thorac Cancer. 2018 Jun;9(6):745-749. doi: 10.1111/1759-7714.12637. Epub 2018 Apr 19.

Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma.

J Thorac Oncol. 2017 Nov;12(11):e188-e190. doi: 10.1016/j.jtho.2017.07.029.

Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.

Clin Breast Cancer. 2020 Aug;20(4):e433-e438. doi: 10.1016/j.clbc.2020.02.003. Epub 2020 Feb 19.

Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.

J Thorac Oncol. 2019 Apr;14(4):e70-e72. doi: 10.1016/j.jtho.2018.11.026.

A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.

J Thorac Oncol. 2019 Nov;14(11):1982-1988. doi: 10.1016/j.jtho.2019.06.015. Epub 2019 Jun 27.

Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.

Clin Lung Cancer. 2021 May;22(3):e390-e394. doi: 10.1016/j.cllc.2020.06.008. Epub 2020 Jun 11.

引用本文的文献

A Phase II Study of Cabozantinib in Patients With -Altered Lung Cancers.

JTO Clin Res Rep. 2025 Jun 5;6(8):100857. doi: 10.1016/j.jtocrr.2025.100857. eCollection 2025 Aug.

A novel mesenchymal epithelial transition (MET) inhibitor, CB538, relieves acquired resistance in -mutated -amplified non-small cell lung cancer.

Transl Cancer Res. 2025 Mar 30;14(3):1915-1927. doi: 10.21037/tcr-24-1614. Epub 2025 Mar 24.

REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?

Transl Lung Cancer Res. 2024 Aug 31;13(8):2082-2086. doi: 10.21037/tlcr-24-144. Epub 2024 Jul 26.

Mutation of as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with Mutation.

Lung Cancer (Auckl). 2024 Aug 27;15:123-128. doi: 10.2147/LCTT.S467584. eCollection 2024.

Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.

J Cancer Res Clin Oncol. 2024 Aug 24;150(8):395. doi: 10.1007/s00432-024-05920-1.

Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein-Ligand Interactions and High Selectivity.

J Med Chem. 2024 Jan 25;67(2):864-884. doi: 10.1021/acs.jmedchem.3c01861. Epub 2024 Jan 10.

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo Amplification in Patients with Metastatic -Mutated NSCLC.

Int J Mol Sci. 2023 Aug 23;24(17):13077. doi: 10.3390/ijms241713077.

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.

JTO Clin Res Rep. 2023 Jun 1;4(8):100533. doi: 10.1016/j.jtocrr.2023.100533. eCollection 2023 Aug.

Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach.

Metabolites. 2023 Jan 21;13(2):162. doi: 10.3390/metabo13020162.

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.

Respir Res. 2023 Jan 25;24(1):28. doi: 10.1186/s12931-023-02329-1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献